Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04862286
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-17
First Post:
2021-04-26
Brief Title:
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous SC Injection of Risankizumab Who Have Completed Participation in Study M19-977
Sponsor:
Organization:
AbbVie
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
132
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: